Abstract:Background: Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Because many hepatocellular carcinomas are already unresectable at the time of initial diagnosis, percutaneous tumor ablation has become established in recent decades as a curative therapeutic approach for very early (BCLC 0) and early (BCLC A) HCC. The aim of this paper is to provide a concise overview of the percutaneous local ablative procedures currently in use, based on their technical characteristics as well as clinical relevance, taking into account the current body of studies. Materials and methods: The literature search included all original papers, reviews, and meta-analyses available via MEDLINE and Pubmed on the respective percutaneous ablation procedures; the primary focus was on randomized controlled trials and publications from the last 10 years. Results and conclusions: Radiofrequency ablation (RFA) and microwave ablation (MWA) are well-established procedures that are considered equal to surgical resection in the treatment of stage BCLC 0 and A HCC with a diameter up to 3 cm due to their strong evidence in international and national guidelines. For tumors with a diameter between 3 and 5 cm, the current S3 guidelines recommend a combination of transarterial chemoembolization (TACE) and thermal ablation using RFA or MWA as combination therapy is superior to thermal ablation alone in tumors of this size and shows comparable results to surgical resection in terms of overall survival. Alternative, less frequently employed thermal procedures include cryotherapy (CT) and laser ablation (LA). Non-thermal procedures include irreversible electroporation (IRE), interstitial brachytherapy (IBT), and most recently, electrochemotherapy (ECT). Due to insufficient evidence, these have only been used in individual cases and within the framework of studies. However, the nonthermal methods are a reasonable alternative for ablation of tumors adjacent to large blood vessels and bile ducts because they cause significantly less damage to these structures than thermal ablation methods. With advances in the technology of the respective procedures, increasingly good evidence, and advancements in supportive techniques such as navigation devices and fusion imaging, percutaneous ablation procedures may expand their indications for the treatment of larger and more advanced tumors in the coming years. Key points: · RFA and MWA are considered equal to surgical resection as a first-line therapy for the curative treatment of stage BCLC 0 and A HCCs with a diameter of up to 3 cm.. · For HCCs with a diameter between 3 and 5 cm, a combination of TACE and RFA or MWA is recommended. This combination therapy yields results comparable to those of surgical resection in terms of overall survival.. · Due to insufficient evidence, alternative ablation methods have only been used in individual cases and within the framework of studies. However, nonthermal methods, such as IRE, IBT, and, most recently, ECT, are a reasonable alternative for ablation of HCCs adjacent to large blood vessels and bile ducts because they cause significantly less damage to these structures than thermal ablation methods.. Citation format: · Luerken L, Haimerl M, Doppler M et al. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Fortschr Röntgenstr 2022; 194: 1075 - 1086.

Percutaneous Thermal Ablation of Medium and Large Hepatocellular Carcinoma: Long-term Outcome and Prognostic Factors

Percutaneous Thermal Ablation Combined with Simultaneous Transarterial Chemoembolization for Hepatocellular Carcinoma ≤5 Cm

Percutaneous Thermal Ablation for the Treatment of Colorectal Liver Metastases and Hepatocellular Carcinoma: a Comparison of Local Therapeutic Efficacy

Mid-term Outcome of Percutaneous Thermal Ablation for Intrahepatic Recurrent Hepatocellular Carcinoma after Liver Transplantation.

Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma

Laparoscopic Microwave Ablation of Hepatocellular Carcinoma at Liver Surface: Technique Effectiveness and Long-Term Outcomes.

Radiofrequency Ablation of Recurrent Hepatocellular Carcinoma after Hepatectomy: Therapeutic Efficacy on Early- and Late-Phase Recurrence

Radiofrequency Ablation of Hepatocellular Carcinoma: Long-Term Outcome and Prognostic Factors

Clinical Analysis of Ultrasound-guided Percutaneous Microwave Ablation for Hepatocellular Carcinoma

Long-Term Outcome Of Percutaneous Radiofrequency Ablation In Recurrent Hepatocellular Carcinoma After Liver Transplantation

Comparison Of Long-Term Effectiveness And Complications Of Radiofrequency Ablation With Hepatectomy For Small Hepatocellular Carcinoma

[Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study]

Outcomes and Complications of Image-Guided Percutaneous Tumour Ablation for Hepatocellular Carcinoma at the Irish National Liver Transplant Centre

Long-term outcome and eligibility of radiofrequency ablation for hepatocellular carcinoma over 3.0 cm in diameter

Long-term Outcomes and Prognostic Analysis of Radiofrequency Ablation for Small Hepatocellular Carcinoma: 10-Year Follow-Up in Chinese Patients

Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation.

Radiofrequency ablation of hepatocellular carcinoma in difficult locations: Strategies and long-term outcomes.

Long-term outcomes of combined radiofrequency ablation and multipronged ethanol ablation for the treatment of unfavorable hepatocellular carcinoma

Long-term efficacy of radiofrequency ablation in 446 patients with hepatocellular carcinoma]

Overall Survival and Disease-Free Survival of Radiofrequency Ablation of Hepatocellular Carcinoma

[Long Term (5 Years) Outcome of Radiofrequency Ablation for Hepatocellular Carcinoma in 256 Cases].